Medius Deal Watch July 2017

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.


  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

Medius Deal Watch September 2017

The trend we have noted previously in the decline in the number of pharma M&A deals continues this month.  If a deal is to be done it is more likely to be a licensing transaction.  In September, the majority of deals were licences and there were more acquisitions of specific assets than company acquisitions.  Those companies that need to raise cash, for example Teva to tackle its debt crisis, continue to announce asset divestments.

Licensor Acquired
Licensee Acquirer
Deal Type Headline ($m)
Halozyme Therapeutics
Licence, collaboration, option 1,865
Teva Pharmaceutical Industries
Acquisition - asset 1,100
Aspen Global
Acquisition - asset 766
Teva Pharmaceutical
CVC Capital Partners
Acquisition - asset 703
Teva Pharmaceutical
Foundation Consumer Healthcare
Acquisition - asset 675
Click here to view the top 20 deals for September

The full report also contains:

  • The top 20 deals of the month
  • The spin out - the deal du jour?
  • Regional deals with a Chinese twist
  • Allergan goes tribal
  • Pricing pressures

Want to read the complete report?


Interested in reading the past issues? 

  • Download the Deal Watch August 2017 HERE
  • Download the Deal Watch July 2017 HERE
  • Download the Deal Watch May 2017 HERE
  • Download the Deal Watch April 2017 HERE
  • Download the Deal Watch March 2017 HERE
  • Download the Deal Watch February 2017 HERE
  • Download the Deal Watch January 2017 HERE
  • Download the 2016 annual review HERE
Navin Thomas
Written By

Add Your Response